Pfizer to expand respiratory drug portfolio with ReViral acquisition
Share
Reuters
7 April 2022
The US drugmaker is to acquire Britain's ReViral for around $525m, to gain access to experimental drugs against the respiratory syncytial virus. ReViral has four RSV therapies in its pipeline, with lead product candidate Sisunatovir in mid-stage studies.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.
We use cookies, which are small text files, to improve your experience on our website. You can allow all or manage them individually. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. View our Cookie Policy here.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
